SCHEMBL1319909

SCHEMBL1319909

COC(=O)c1ccc(C(=O)/C=C/c2ccc(/C=C/C(=O)NO)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.73
LMNA P02545 3/20 0.73
NPC1 O15118 2/20 0.73
HDAC3 O15379 7/20 0.67
HDAC1 Q13547 7/20 0.67
HDAC2 Q92769 7/20 0.67
HDAC8 Q9BY41 7/20 0.67
HDAC6 Q9UBN7 7/20 0.67
HDAC4 P56524 6/20 0.67
HDAC7 Q8WUI4 6/20 0.67
HDAC10 Q969S8 6/20 0.67
HDAC11 Q96DB2 6/20 0.67
HDAC9 Q9UKV0 6/20 0.67
HDAC5 Q9UQL6 6/20 0.67
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
ATM Q13315 1/20 0.63
NPSR1 Q6W5P4 1/20 0.63
RAB9A P51151 2/20 0.60
HTT P42858 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1319910 1.00 MAPT (0.73) MAPTLMNANPC1HDAC3HDAC1
SCHEMBL1321125 0.86 HDAC3 (0.82) MAPTLMNANPC1HDAC3HDAC1
SCHEMBL1321123 0.86 HDAC3 (0.82) MAPTLMNANPC1HDAC3HDAC1
SCHEMBL25201232 0.86 MAPT (0.75) MAPTLMNANPC1MEN1KMT2A
SCHEMBL3362903 0.86 MAPT (0.75) MAPTLMNANPC1HDAC3HDAC1
SCHEMBL25204220 0.86 MAPT (0.75) MAPTLMNANPC1MEN1KMT2A
SCHEMBL2690446 0.86 MAPT (0.75) MAPTLMNANPC1HDAC3HDAC1
SCHEMBL1320619 0.85 MAPT (0.66) MAPTLMNANPC1HDAC3HDAC1
SCHEMBL1320617 0.85 MAPT (0.66) MAPTLMNANPC1HDAC3HDAC1
SCHEMBL3444240 0.82 HDAC3 (0.71) MAPTLMNANPC1HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814850-B9 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2015-02-25 EP claimed
EP-1814850-B1 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2013-07-03 EP claimed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US claimed
US-7803800-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2010-09-28 US claimed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US claimed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US claimed
EP-1814850-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2007-08-08 EP claimed
WO-2006037761-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2006-04-13 WO claimed
EP-1814850-B9 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2015-02-25 EP disclosed
EP-1814850-B1 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2013-07-03 EP disclosed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US disclosed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US disclosed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US disclosed
US-7803800-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2010-09-28 US disclosed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US disclosed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US disclosed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US disclosed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US disclosed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US disclosed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS HDAC1, HDAC3, HDAC11 MAPT 3303/4885LMNA 895/4885NPC1 2600/4885
US-20080096889-A1 Histone Deacetylases Inhibitors HDAC1, HDAC3, HDAC11 MAPT 3192/4885LMNA 712/4885NPC1 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.